Photocure ASA

Photocure ASA: Exercise of employee share options

Oslo, Norway, 26 March 2021: Reference is made to the stock exchange release by

Photocure ASA ("Photocure" or the "Company") published on 25 March 2021

regarding exercise of share options.

The price for option shares sold by primary insiders have been determined at a

price of NOK 130.6672 per share.

The primary insiders having exercised options have used the net proceeds from

the sale of option shares to purchase shares in Photocure at a price per share

of NOK 130.6672 as follows:

· Dan Schneider, CEO, has purchased 17,980 shares.

· Erik Dahl, CFO, has purchased 3,236 shares.

· Geoffrey Coy, VP and General Manager of U.S. Operations, has purchased 8,081

shares.

· Grete Hogstad, VP Global Strategic Marketing & Business Development, has

purchased 1,872 shares.

· Kari Myren, VP Global Medical Affairs and Clinical Development, has

purchased 1,872 shares.

The shares are purchased at the stated price from Photocure's holding of own

shares. Following the transaction Photocure will hold 15,666 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19

are attached.

For further information, please contact:

Photocure

CFO Erik Dahl

Tel: +47 450 55 000

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading

Act.

AI Terminal